CG Oncology Inc. (CGON) exhibits 41.0% gross margins and -20.8% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 24.0x enterprise multiple and 7.1% implied options volatility.
Sustained 41.0% gross profitability converts into -12.1% operating margin and -20.8% ROIC, outpacing sector cost of capital.
ROIC: -20.8% // GM: 41.0%YoY revenue trajectory of +8.8% paired with -2.35% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +8.8% // FCF YLD: -2.35%Altman Z-Score of 26.00 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 26.00 // F-SCORE: 5/9Trading at 24.0x trailing P/E (20.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±7.1% implied move with a 0.87 put/call ratio around $62.00 max pain.
IMPL MOVE: ±7.1% // P/C: 0.87Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend -10.2% net margins.
NET MARGIN: -10.2% // D/E: 0.00x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for CGON & activate live FRED threshold breach alerts.